+23648073gothi_gothi@gothi.gov.egالأحد إلى الخميس — 8:00 ص إلى 3:00 م--:--:--
العاصمة الإدارية الجديدة — الحي الحكومي
الهيئة العامة للمستشفيات والمعاهد التعليميةالهيئة العامة للمستشفيات والمعاهد التعليميةGOTHI — Teaching Hospitals & Institutesنساعد في تطوير المستقبل الطبى لمصر
تواصل معنا
الرئيسية
عن الهيئة

عن الهيئة

عرض الكل

قائمة عن الهيئة

7 عنصرًا
  • من نحن
  • كلمة رئيس الهيئة
  • الرؤية و الرساله والقيم
  • مجلس الإدارة
  • الهيكل الإدارى
  • بروتوكولات التعاون
  • القواعد واللوائح
التثقيف و التوعيه الصحية
المستشفيات والمعاهد
معاهد ومدارس التمريض
المركز الاعلامى

المركز الاعلامى

عرض الكل

قائمة المركز الاعلامى

5 عنصرًا
  • أخبار الهيئة
  • إنجازات طبية
  • الفاعليات و المؤتمرات
  • زيارات
  • المكتبة الإعلامية
الخدمات
خدمات بحثية4
  • منصة الأبحاث
  • المجلة العلمية
  • المكتبة الالكترونية
  • لجنة أخلاقيات البحث العلمي
خدمات تدريبيه3
  • مركز تدريب رئاسة الهيئة
  • البورد العربي
  • ايفاد التدريب
خدمــات طبيه متمـيزة6
  • المبادرات الرئاسية
  • مركز دعم الباحثين
  • جائزة النشر الدولية
  • نبذه عن دعم الباحثين
  • خدمات مركز دعم الباحثين
  • اتصل بنا
عرض جميع الخدمات
Gothi Profile
الرئيسيةعن الهيئةالتثقيف و التوعيه الصحيةالمستشفيات والمعاهدمعاهد ومدارس التمريضالمركز الاعلامىالخدماتGothi Profile
GOTHI

الهيئة العامة للمستشفيات والمعاهد التعليمية

GOTHI — Teaching Hospitals & Institutes

نساعد في تطوير المستقبل الطبى لمصر

إقرأ من الموقع

  • اتفاقيات و بروتوكلات تعاون
  • دعم الباحثين
  • التثقيف والتوعية الصحية
  • المركز الإعلامي
  • الدلائل الارشادية
  • بروتوكولات الطوارئ

روابط هامة

  • وزارة الصحة والسكان
  • بنك المعرفة المصري
  • ١٠٠ مليون صحة
  • منظومة الشكاوى الحكومية الموحدة
  • مركز تدريب هيئة المستشفيات التعليمية

تواصل معنا

  • مواعيد العمل: من الأحد إلي الخميس — 8:00 ص حتى 3:00 م
  • العاصمة الإدارية الجديدة — الحي الحكومي
  • +23648073
  • gothi_gothi@gothi.gov.eg
جميع الحقوق محفوظة © 2026 — الهيئة العامة للمستشفيات والمعاهد التعليميةSINCE 1975
  1. الرئيسية
  2. الدلائل الإرشادية
  3. طب بشرى
  4. طب غدد صماء وسكري

طب غدد صماء وسكري

Clinical Guideline · 01

Glycemic Targets

last update: 30 April 2024”
Download Guideline
– Executive Summary11 بندعرض التوصيات
“last update: 30 April 2024”                                                                                                       Download Guideline
 

– Executive Summary

 

This guideline offers evidence-based recommendations on the targeted levels of blood glucose. The recommendations are intended to provide healthcare professionals with practical guidance on monitoring of blood glucose and improving health outcomes for people living with Diabetes.

Recommendations

 

l  Glycemic status should be assessed at least twice a year using HbA1c and/or suitable continuous glucose monitoring (CGM) parameters. Individuals who are not fulfilling treatment objectives, have frequent or severe hypoglycemia or hyperglycemia, have fluctuating health status, or are growing and developing in adolescence should be assessed more regularly (every three months). (Good practice statement)

l  Glycemic status should be assessed at least quarterly and as needed in people whose therapy has recently changed and/or who are not achieving their glycemic targets. (Good practice statement)

l  An HbA1c target for many nonpregnant adults of <7% without significant hypoglycemia is recommended. (strong recommendation)

l  Time in range is associated with the risk of microvascular complications and can be used for assessment of glycemic control. Additionally, time below range and time above range are useful parameters for the evaluation of the treatment plan.                        (Conditional recommendation).

l  If using an ambulatory glucose profile/glucose management indicator to assess glycemia, a parallel goal for many nonpregnant adults is TIR >70% with time below range <4% and time <54 mg/dL <1%. For those with frailty or at high risk of hypoglycemia, a goal of >50% TIR with <1% time below range is recommended. (Conditional recommendation).

l  On the basis of health care professional judgment and patient preference, achievement of lower HbA1c levels than the goal of 7% may be acceptable and even beneficial if it can be achieved safely without significant hypoglycemia or other adverse effects of treatment.  (Strong recommendation)

l  Less stringent HbA1c targets (such as <8% may be appropriate for patients with limited life expectancy or where the harms of treatment are greater than the benefits. (Strong recommendation).

l  Healthcare professionals should consider deintensification of therapy if appropriate to reduce the risk of hypoglycemia in patients with inappropriate stringent HbA1c targets.  (Strong recommendation).


 

Clinical Guideline · 02

Prevention or Delay of Type 2 Diabetes Mellitus

last update: 14 February 2024”
Download Guideline
– Executive Summary4 بندعرض التوصيات
“last update: 14 February 2024”                                                                                                  Download Guideline
 

– Executive Summary

 

The prevalence of diabetes is globally increasing with a high incidence of complications. Targeted interventions and support are important in this high-risk group. Globally, more than 570 million adults live with diabetes so Prevention or delay of type 2 diabetes Mellitus (T2DM) is of great importance.

This guideline offers evidence-based recommendations for the prevention of diabetes. The recommendations are intended to provide healthcare professionals with practical guidance on preventing or delaying diabetes and associated co-morbidities improving healthy lifestyles for people with high risk of type 2 diabetes.

 

Clinical Guideline · 03

Recommendations

الملخص التنفيذي والتوصيات7 بندعرض التوصيات
 

l  Refer adults with overweight/obesity at high risk of type 2 diabetes, to an intensive lifestyle behavior change program for a weight reduction of at least 7% of initial body weight through a healthy reduced-calorie diet and 150 min/week of moderate-intensity physical activity. (Strong recommendation).

l  A variety of eating patterns should be considered to prevent diabetes in individuals with prediabetes. Including Mediterranean diet, low carbohydrate eating plan, low fat, DASH diet (Dietary approaches to stop hypertension) (Strong recommendation)

l  Prescribe metformin for prevention of T2DM in adult individuals with prediabetes, 25-59 years, those with high BMI ≥35 kg/m2, higher fasting plasma glucose 100 – 125 mg/dL, higher HbA1C 5.7 – 6.4%, women with prior GDM   (strong recommendation)

l  Prediabetes is associated with heightened cardiovascular risk; therefore, screening for and treatment of modifiable risk factors for cardiovascular disease should be considered. (Strong recommendation)

l  More intensive preventive approaches should be considered in individuals who are at particularly high risk of progression to diabetes, including individuals with BMI ≥35 kg/m2, those at higher glucose levels (e.g., fasting plasma glucose 100 –125 mg/dL, 2-h postprandial glucose 140 – 199 mg/dL, A1C 5.7 – 6.4%), and individuals with a history of gestational diabetes mellitus (strong recommendation)

l  Pharmacotherapy should be considered to achieve sustained weight loss, minimize the progression of hyperglycemia, and cardiovascular risk reduction. (strong recommendation)


 

  Jump to activity

Clinical Guideline · 04

Pharmacological Approach to Type 1 Diabetes in Adults

last update: 21 January 2025”
Download Guideline
– Executive Summary10 بندعرض التوصيات
“last update: 21 January 2025”                                                                                                    Download Guideline

   

– Executive Summary

 

The prevalence of type 1 diabetes is globally increasing around 2 million with high incidence of acute and chronic complications and the majority of the patients remain uncontrolled despite the presence of many insulin regimens and many new insulin analogues as well as the great improvement of insulin delivery systems.

This guideline provides recommendations for the pharmacological approach to type1 diabetes in adults.

➡️Recommendations

▪️ Treat most adults with type 1 diabetes with multiple daily doses of prandial and basal insulin                                                                      Strong recommendation

▪️ For most adults with type 1 diabetes, insulin analogs are preferred over injectable human insulins to minimize hypoglycemia risk.        Conditional recommendation 

▪️  Automated Insulin delivery systems (insulin pens) and insulin analogues could be considered for all adults with type 1 diabetes.        Conditional  recommendation

▪️ To improve glycemic outcomes and quality of life and minimize hypoglycemia risk, most adults with type 1 diabetes should receive education on how to match mealtime insulin doses to carbohydrate intake and, additionally, to fat and protein intake. They should also be taught how to modify the insulin dose (correction dose) based on concurrent glycemia, glycemic trends (if available), sick-day management, and anticipated physical activity.              Strong  recommendation

▪️  Insulin treatment plan and insulin-taking behavior should be reevaluated at regular intervals (e.g., every 3–6 months) and adjusted to incorporate specific factors that impact choice of treatment and ensure achievement of individualized glycemic goals.                                                                                 Good practice statement


 

  Jump to activity

Clinical Guideline · 05

Diabetes Care in Hospital Settings

last update: 21 January 2025”
Download Guideline
– Executive Summary2 بندعرض التوصيات
“last update: 21 January 2025”                                                                                                      Download Guideline
 

– Executive Summary

 

This guideline offers evidence-based recommendations on the inpatient management of diabetic patients during hospital stay. The recommendations are intended to provide healthcare professionals with practical guidance on the proper way to manage diabetes and dysglycemia during hospitalization.

Clinical Guideline · 06

Pharmacological Approach of Type 2 Diabetes Mellitus

last update: 20 November 2025”
Download Guideline
الملخص التنفيذي والتوصياتعرض التوصيات
“last update: 20 November  2025”                                                                                          Download Guideline
 
– Executive Summary
 
This guideline offers evidence-based recommendations on pharmacotherapy for type 2 diabetes in adults. The recommendations are intended to provide healthcare professionals with practical guidance on Pharmacological Approach of Type 2 Diabetes Mellitus and improving health outcomes for people living with Diabetes.